The next few years will be a critical period for many Sponsors introducing cell and gene therapies to market as they ramp up their manufacturing and quality assurance capabilities. Unlike with traditional small molecules that are produced with recipe-driven, high-volume batch processes, cell and gene therapies require a wholly different manufacturing strategy. And production necessarily involves a wide network of trusted providers outside of the factory walls.
Read what companies entering this space will need to consider in re-examining their manufacturing and quality assurance practices and see our blueprint for making forward-looking investment decisions.
